Advertisement

PharmacoEconomics & Outcomes News

, Volume 819, Issue 1, pp 23–23 | Cite as

Genotype-guided therapy reduces toxicity, saves costs

Clinical study
  • 2 Downloads

Reference

  1. Henricks LM, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer 107: 60-67, 10 Dec 2018. Available from: URL: http://doi.org/10.1016/j.ejca.2018.11.010 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations